美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Novo Nordisk A/S B Shares ADRhedged

23.23

-0.5284-2.22%

盤後：23.380.1473+0.63%16:15 EDT

成交量：453

成交額：1.06萬

市值：418.19萬

市盈率：- -

高：23.38

開：23.38

低：23.23

收：23.76

52周最高：34.36

52周最低：19.00

股本：18.00萬

流通股本：18.00萬

量比：0.47

換手率：0.25%

股息：1.69

股息率：7.29%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

從GLP-1先行者到被禮來反超，諾和諾德如何一步步丟掉減重藥領先優勢

老虎资讯综合

金錢語錄：諾和諾德CEO談併購

美銀首席執行官：公司每年為員工支出2.5億美元用於報銷GLP-1減重藥物

环球市场播报

相差百億美元！全球第一大藥王與第二大藥王銷售差距在拉大

二季度利潤亮眼股價卻下跌近6% 口服減重藥能撐起諾和諾德的中長期預期嗎？

每日经济新闻

諾和諾德：海牙法院針對 Ceban 下達臨時禁令。

諾和諾德贏得荷蘭法院禁令，保護患者免受未經批准的非法複方司美格魯肽鼻噴霧劑的侵害。

國產藥加速追趕減重明星賽道進入「群雄逐鹿」時代

諾和諾德首席執行官：相較於注射劑，口服版 Wegovy 的市場需求之高，讓我們愈發感到意外。

諾和諾德股價下跌6.8%，觸及盤中低點。

諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。

諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。

諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。

諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。

諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。

諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低

环球市场播报

諾和諾德首席執行官：目前無意開展重大轉型式收購交易。

諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。

諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂

諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/NVOH/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":23.2327,"timestamp":1789502400000,"preClose":23.7611,"halted":0,"volume":453,"hourTrading":{"tag":"盘后","latestPrice":23.38,"preClose":23.2327,"latestTime":"16:15 EDT","volume":8,"amount":185.5962,"timestamp":1789503300268,"change":0.1473,"changeRate":0.00634,"amplitude":0},"delay":0,"changeRate":-0.022238027700737666,"floatShares":180001,"shares":180001,"eps":0,"marketStatus":"已收盤","change":-0.5284,"latestTime":"09-15 16:00:00 EDT","open":23.38,"high":23.38,"low":23.2327,"amount":10593,"amplitude":0.006199,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":23.7611,"nav":23.761042,"aum":4277011.321042,"dividendRate":0.072923,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.38,"preClose":23.2327,"latestTime":"16:15 EDT","volume":8,"amount":185.5962,"timestamp":1789503300268,"change":0.1473,"changeRate":0.00634,"amplitude":0},"volumeRatio":0.47109,"impliedVol":0.2429,"impliedVolPercentile":0.5739},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":180001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.47109,"shares":180001,"dividePrice":1.6942,"high":23.38,"amplitude":0.006199,"preClose":23.7611,"low":23.2327,"week52Low":19,"pbRate":"--","week52High":34.36,"institutionHeld":0,"latestPrice":23.2327,"eps":0,"divideRate":0.072923,"volume":453,"delay":0,"ttmEps":0,"open":23.38,"prevYearClose":27.4362,"prevWeekClose":23.4261,"prevMonthClose":24.5859,"prevQuarterClose":26.0576,"fiveDayClose":24.5207,"twentyDayClose":24.4193,"sixtyDayClose":23.4494},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"NVOH","amount":0.76666,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"NVOH","amount":0.27495,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.27495,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.76666,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183741843","title":"從GLP-1先行者到被禮來反超，諾和諾德如何一步步丟掉減重藥領先優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=1183741843","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183741843?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 10:33","pubTimestamp":1785983625,"startTime":"0","endTime":"0","summary":"诺和诺德曾凭借Ozempic和Wegovy率先打开GLP-1减重药市场，并一度成为欧洲市值最高的上市公司。但随着产能不足、美国直销渠道布局偏慢以及研发管线对司美格鲁肽依赖较深，先发优势逐渐被削弱。与此同时，礼来凭借Zepbound、Mounjaro以及更丰富的下一代减重药管线实现反超。如今，诺和诺德正在通过组织调整、扩大产能和加快新品商业化重新追赶，而真正决定未来竞争格局的，仍是下一代产品能否重新建立差异化优势。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7ec85b2c1f723f3e05278a0cd609e815","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7ec85b2c1f723f3e05278a0cd609e815"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLYZ","LLY","NVOX","ELIS","LLYX","ELIL","LLII","NVOH","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135937164","title":"金錢語錄：諾和諾德CEO談併購","url":"https://stock-news.laohu8.com/highlight/detail?id=1135937164","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135937164?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 01:49","pubTimestamp":1785952183,"startTime":"0","endTime":"0","summary":"“我不清楚那两家正试图互相接洽的竞争对手究竟有何需求，但我们目前看不到进行变革性并购的必要性。”——这是Ozempic生产商诺和诺德（Novo Nordisk）的首席执行官迈克·杜斯特德（Mike Doustdar）在接受《华尔街日报》采访时所言。此番言论针对的是近期《金融时报》的一篇报道，该报道称阿斯利康（AstraZeneca）与百时美施贵宝（Bristol Myers Squibb）曾就潜在合并事宜进行过商谈。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","IE00BKVL7J92.USD","BK4599","BK4532","NVO","THNR","BK4585","BK4588","OZEM","PPH","IE00BZ1G4Q59.USD","NVOH","BK4007","NVOX","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529184","title":"美銀首席執行官：公司每年為員工支出2.5億美元用於報銷GLP-1減重藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529184","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529184?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 00:44","pubTimestamp":1785948240,"startTime":"0","endTime":"0","summary":"美银首席执行官布莱恩莫伊尼汉周三接受采访称，美国银行每年花费逾 2.5 亿美元，承担员工使用 GLP-1 减重药物的费用。根据莫伊尼汉给出的数据，美银每年为约 21.1 万名员工预留合计超 20 亿美元医疗预算；仅 GLP-1 药物一项，如今就占到全部医疗开支的约 13%。“我们在 GLP-1 药物上投入大约 2.5 亿美元甚至更多，而四五年前这项支出还是零。”这家全美资产规模第二大的银行，同时依托自身庞大的采购体量，与药企、药房福利管理机构谈判压低药价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-06/doc-inimhyac1066977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4144","JDOC","NVOH","GLP","BK4590","NVOX","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657998525","title":"相差百億美元！全球第一大藥王與第二大藥王銷售差距在拉大","url":"https://stock-news.laohu8.com/highlight/detail?id=2657998525","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657998525?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 22:54","pubTimestamp":1785941698,"startTime":"0","endTime":"0","summary":"礼来的替尔泊肽与诺和诺德的司美格鲁肽，在2025年分别成为全球销售额第一大、第二大药物，但这两大GLP-1药物之间的销售额差距在拉大。8月5日晚间，礼来公布的半年报显示，2026年上半年，替尔泊肽（降糖适应证产品Mounjaro和减重适应证产品Zepbound）合计收入达到276.93亿美元，同比大增近88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832918043.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832918043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FHLC","SG9999014880.SGD","HRTS","LU0320765059.SGD","LU2023251221.USD","LU2896262040.SGD","LU0786609619.USD","LU2461242641.AUD","SG9999001176.SGD","LU2023250504.SGD","CANC","LU1804176565.USD","SG9999001176.USD","SGXZ81514606.USD","LU2265009873.SGD","LU0823434740.USD","LU0109391861.USD","LU0323591593.USD","LU0345770993.USD","LU2237443978.SGD","LU2417539215.USD","AGNG","LU0820562030.AUD","LU1868837300.USD","LU0820561909.HKD","BK4585","LU0210536198.USD","LU1989771016.USD","LU1917777945.USD","LU2236285917.USD","LU0345770308.USD","LU2357305700.SGD","LU2168564495.EUR","SG9999013999.USD","GB00BDT5M118.USD","VHT","PJP","LU0820561818.USD","IE00BKPKM429.USD","IE00BK4W5L77.USD","LU1551013342.USD","TMED","SGXZ31699556.SGD","LU2552382058.USD","SG9999014914.USD","LU0174119429.USD","LU2324357040.USD","LU0106261372.USD","LU2271345857.HKD","LU0823416689.USD","IE0009355771.USD","LU1023059063.AUD","LU0471298777.SGD","LU0198837287.USD","LU1267930730.SGD","LU2361044949.HKD","LU0289739699.SGD","LU0354030511.USD","LU1323610961.USD","LU2063271972.USD","IE00BJT1NW94.SGD","LU2023250330.USD","IHE","LU2264538146.SGD","LU0097036916.USD","ILDR","LU2361045086.USD","SG9999015945.SGD","LU0079474960.USD","LU1127390331.HKD","LU2168563687.JPY","LU0256863902.USD","IE00BFSS7M15.SGD","LU0122379950.USD","XLV","LU2471134879.HKD","LU0203201768.USD","LU2746668974.SGD","IE00BZ1G4Q59.USD","LU0882574055.USD","LU0432979614.USD","MHIP","GDOC","LU0353189763.USD","LU2111349929.HKD","LU2237443549.SGD","MEDX","OZEM","IE0004445015.USD","PPH","LLII","IE00BJLML261.HKD","MEDI","NVOX","LU1145028129.USD","IE00B7KXQ091.USD","BK4599","LU1291159041.SGD","LU1988902786.USD","LU2211815571.USD","LU2756315318.SGD","THNR","BK4534","LU0256863811.USD","FTXH","LU2237443465.HKD","LU2360106947.USD","IE00B2B36J28.USD","LU0058720904.USD","LU2168564065.EUR","SG9999018865.SGD","LU2471134952.CNY","IE00BKVL7J92.USD","LU0225283273.USD","LU0354030438.USD","LU2168564222.USD","LU2089984988.USD","SG9999014906.USD","LU2491050154.USD","BK4007","LU0234572021.USD","NVOH","LU2471134523.USD","LU1712237335.SGD","LU0094547139.USD","LU0006306889.USD","LU1868837136.USD","SGXZ99366536.SGD","LU2491050071.SGD","BK4516","LU1548497426.USD","LU0943347566.SGD","LU0787776722.HKD","JDOC","LU1366192091.USD","LU1974910355.USD","LU2361044865.SGD","LU0823434583.USD","LU2108987350.USD","LU1064131342.USD","LU2112291526.USD","LU1720051017.SGD","LU2746668461.USD","IE00B4R5TH58.HKD","IE0005OL40V9.USD","LU1232071149.USD","LU1551013425.SGD","LU0158827781.USD","ELIL","LU1280957306.USD","LU2089283258.USD","LU1093756168.USD","LU2087625088.SGD","LU0456855351.SGD","IE00B1BXHZ80.USD","LLY","LU1979441026.SGD","NVO","LU1814569148.SGD","LU0672654240.SGD","LU0466842654.USD","LU0203202063.USD","IXJ","IE00BJJMRY28.SGD","IE0002141913.USD","LU1868836757.USD","LU2106854487.HKD","SG9999017495.SGD","IE00B4JS1V06.HKD","BK4588","LU1069344957.HKD","LU2756315664.SGD","LU0882574139.USD","IE0001KFT4U8.USD","IE00BFSS8Q28.SGD","LLYX","RXL","CURE","LU0353189680.USD","LU1057294990.SGD","LU1623119135.USD","SG9999015952.SGD","BK4532","BK4581","SGXZ51526630.SGD","LU1061106388.HKD","LU0964807845.USD","LU2237438978.USD","LU2750360997.AUD","LU0385154629.USD","LU0061475181.USD","LU1035775433.USD","LU0708995401.HKD","LU2456880835.USD","LU0238689110.USD","LU1720051108.HKD","LU2237443895.HKD","IE00BKDWB100.SGD","LU0417517546.SGD","LU0316494557.USD","LU0154236417.USD","LU2089284900.SGD","IE0004445239.USD","LLYZ","LU1868836914.USD","LU2462157665.USD","LU0889565916.HKD","SG9999015978.USD","LU1868836591.USD","SG9999014898.SGD","LU1093756325.SGD","LU0133085943.USD","LU2028103732.USD","BK4533","LU0683600562.USD","LU2237443622.USD","LU2237443382.USD","LU2471134796.USD","LU0689472784.USD","IE00BN29S564.USD","LU2462591350.SGD","LU2491049909.HKD","LU0109394709.USD","LU2168564149.EUR","IE00BJJMRX11.SGD","LU0096364046.USD","IE00BJJMRZ35.SGD","SG9999015986.USD","IE00B1XK9C88.USD","LU2552382132.HKD","ELIS","LU0471298694.HKD","SG9999018857.SGD","IYH","LU2213496289.HKD","SGXZ57979304.SGD","LU0640476718.USD","LU1629891620.HKD","IE00BK4W5M84.HKD","WDNA","LU0158827948.USD","LU0266013472.USD","LU1983299246.USD","LU0114720955.EUR","LU2552382215.SGD","LU0320765992.SGD","IE00B775H168.HKD","LU2602419157.SGD","IE00BWXC8680.SGD","IE00BFTCPJ56.SGD","LU2468319806.SGD","TRUH","LU2750360641.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657528844","title":"二季度利潤亮眼股價卻下跌近6% 口服減重藥能撐起諾和諾德的中長期預期嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657528844","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657528844?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:50","pubTimestamp":1785937800,"startTime":"0","endTime":"0","summary":"二季度利润超预期、上调全年指引，却遭遇美股下跌6%；口服GLP-1药物Wegovy商业化取得突破，但下一代核心CagriSema两次头对头败给礼来替尔泊肽。在千亿美元减肥药赛道，诺和诺德正经历从“霸主”到激烈博弈的转变，增长的希望与风险高度集中于口服GLP1这条路线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832855655.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832855655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU0154236417.USD","OZEM","IE00BZ1G4Q59.USD","PPH","BK4532","BK4585","LU1093756325.SGD","BK4007","NVO","NVOX","BK4599","THNR","NVOH","LU1093756168.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657238540","title":"諾和諾德：海牙法院針對 Ceban 下達臨時禁令。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657238540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657238540?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:44","pubTimestamp":1785937442,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4599","LU0154236417.USD","BK4585","PPH","LU1093756325.SGD","OZEM","LU1093756168.USD","THNR","NVOX","NVO","BK4007","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540463","title":"諾和諾德贏得荷蘭法院禁令，保護患者免受未經批准的非法複方司美格魯肽鼻噴霧劑的侵害。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540463?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:43","pubTimestamp":1785937380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","NVOH","OZEM","LU0154236417.USD","BK4588","LU1093756325.SGD","PPH","BK4532","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","BK4599","NVO","IE00BKVL7J92.USD","THNR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547441","title":"國產藥加速追趕 減重明星賽道進入「群雄逐鹿」時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547441","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547441?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:07","pubTimestamp":1785935232,"startTime":"0","endTime":"0","summary":"新华财经上海8月5日电2026年，我国“体重管理年”三年行动进入收官之年。当前，全民体重管理意识和技能显著提升，健康生活方式更加普及，部分人群体重异常状况得到改善。体重管理催生了减重经济。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832808212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832808212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVOX","RSPH","NVOC","MEDI","NVOH","THNR","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657073541","title":"諾和諾德首席執行官：相較於注射劑，口服版 Wegovy 的市場需求之高，讓我們愈發感到意外。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657073541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657073541?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 20:04","pubTimestamp":1785931485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756325.SGD","THNR","LU0154236417.USD","NVO","OZEM","BK4588","BK4007","BK4532","BK4599","PPH","NVOH","NVOX","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657490745","title":"諾和諾德股價下跌6.8%，觸及盤中低點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657490745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657490745?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:43","pubTimestamp":1785930191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","LU1093756168.USD","BK4599","BK4007","LU0154236417.USD","THNR","IE00BKVL7J92.USD","OZEM","NVOX","BK4585","PPH","LU1093756325.SGD","NVO","NVOH","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657003549","title":"諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657003549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657003549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:42","pubTimestamp":1785930157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","BK4588","NVOH","BK4532","LU1093756168.USD","NVO","IE00BKVL7J92.USD","PPH","LU1093756325.SGD","NVOX","BK4007","BK4599","LU0154236417.USD","BK4585","THNR","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657539549","title":"諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657539549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657539549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:23","pubTimestamp":1785929036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","BK4588","BK4532","IE00BZ1G4Q59.USD","LU1093756168.USD","NVO","IE00BKVL7J92.USD","NVOH","OZEM","THNR","BK4585","PPH","LU0154236417.USD","LU1093756325.SGD","NVOX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510014","title":"諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:06","pubTimestamp":1785924365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","BK4588","BK4532","LU0154236417.USD","LU1093756325.SGD","THNR","IE00BKVL7J92.USD","NVOH","NVO","LU1093756168.USD","BK4007","BK4585","NVOX","PPH","IE00BZ1G4Q59.USD","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657107295","title":"諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657107295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657107295?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:03","pubTimestamp":1785924200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756168.USD","BK4585","PPH","BK4588","IE00BKVL7J92.USD","THNR","IE00BZ1G4Q59.USD","NVOX","BK4007","NVOH","NVO","OZEM","LU1093756325.SGD","LU0154236417.USD","BK4532","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510267","title":"諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510267?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:01","pubTimestamp":1785924082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","LU1093756168.USD","OZEM","NVOH","BK4588","LU1093756325.SGD","BK4532","LU0154236417.USD","NVO","NVOX","IE00BKVL7J92.USD","BK4585","IE00BZ1G4Q59.USD","THNR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657551275","title":"諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657551275","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657551275?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:02","pubTimestamp":1785920520,"startTime":"0","endTime":"0","summary":"投资者持续聚焦价格压力、业绩超预期的可持续性，以及 Wegovy 口服片剂能否成为足够强劲的增长引擎，扭转公司增长颓势。诺和诺德坦言，产品降价持续拖累销售收入。不过 CEO 迈克杜斯塔达尔表示，销量持续攀升叠加 Wegovy 口服片剂初期销售表现，证明当前经营策略行之有效。周三交易开盘前，诺和诺德丹麦本土个股年内累计下跌约 5%；尽管 Wegovy 口服片剂上市后股价有所修复，但较 2024 年年中高点仍大跌近 70%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimhawm4660383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0154236417.USD","BK4007","BK4532","IE00BZ1G4Q59.USD","PPH","LU1093756168.USD","IE00BKVL7J92.USD","LU1093756325.SGD","NVOX","BK4588","BK4585","THNR","NVO","BK4599","NVOH","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511799","title":"諾和諾德首席執行官：目前無意開展重大轉型式收購交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511799?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:30","pubTimestamp":1785918656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","OZEM","LU1093756325.SGD","NVOH","NVO","BK4007","BK4532","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","PPH","THNR","BK4585","LU0154236417.USD","BK4599","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511459","title":"諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511459?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:26","pubTimestamp":1785918369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","NVO","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","PPH","BK4007","LU1093756325.SGD","THNR","BK4532","NVOH","IE00BZ1G4Q59.USD","OZEM","LU0154236417.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519148","title":"諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519148?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:49","pubTimestamp":1785916176,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德Q2业绩超预期、上调全年指引却难掩隐忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4007","NVO","NVOX","BK4588","LU1093756325.SGD","LU0154236417.USD","BK4599","THNR","IE00BKVL7J92.USD","PPH","OZEM","LU1093756168.USD","BK4585","IE00BZ1G4Q59.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2657403515","title":"諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢","url":"https://stock-news.laohu8.com/highlight/detail?id=2657403515","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657403515?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:00","pubTimestamp":1785913213,"startTime":"0","endTime":"0","summary":"“Cagrisema再次令人失望，这可能凸显了诺和诺德面临的最大战略问题。”他表示，这些令人失望的结果将促使诺和诺德加快研发步伐并更加积极地寻求合作机会，而非变得更加谨慎。“这将诺和诺德的研发管线及其稳健性推到了聚光灯下，”AL Sydbank在致客户的报告中表示，并补充道，尽管诺和诺德的业绩本应让投资者松一口气，但这些数据和减值准备却打击了市场情绪。他表示，当务之急是扩大研发管线，同时保持生产效率的纪律性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","LU0154236417.USD","NVO","THNR","IE00BKVL7J92.USD","BK4588","BK4585","BK4532","BK4007","LU1093756168.USD","PPH","BK4599","NVOH","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}